Drug lookup
Drug reference

Megestrol acetate

Progestogen · Unknown

ProgestogenUnknownATC null
CDSCO approvedSchedule H
EXCRETION
not curated
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 3
  • DofetilideSevereDatabaseDDInter
  • ThalidomideSevereDatabaseDDInter

Mechanism

Megestrol acetate is a C21 steroid in the pregnane family with selective activity very similar to that of progesterone itself. Progesterone's main function is the preparation of the uterus for nidation and maintenance of pregnancy by preventing endometrial shedding, decreasing uterine motility, and inhibiting immunological rejection of the foetus through T-cell function and cell-mediated immunity depression.

Indications

Management of endometrial carcinomaMetastatic hormone-dependent breast cancer (use has been largely superseded by tamoxifen and AIs)Appetite stimulant and to restore a sense of well-being in cachectic patients with advanced stages of cancer and AIDSRefractory hot flashes in women

Dosing

Adult
30 micrograms. 500 micrograms. 75 micrograms. 30 micrograms

Pharmacokinetics

Duration
1 –3 days

Side effects

Common
Impaired glucose toleranceIncreased LDL cholesterol levelsDecreased HDL cholesterol levelsWeight gainNauseaVomitingEdemaBreakthrough bleedingShortness of breath
Serious
  • Thrombophlebitis
  • Pulmonary embolism

Pregnancy & lactation

Pregnancy

X

Drug interactions

Dofetilide
Severe
Database

Clinical effect not specified

Source: DDInter

Thalidomide
Severe
Database

Clinical effect not specified

Source: DDInter

Indinavir
Moderate
Textbook

Decreased plasma levels and potentially reduced efficacy of indinavir.

Monitor indinavir levels and clinical response; adjust indinavir dose as necessary or consider alternative therapies.

Source: G&G 14e · p1447

9 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.

Related guidelines

Other Progestogen drugs

Ask House about Megestrol acetate

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Goodman & Gilman 14e, Harrison 22e, BNF·Verified: 2026-05-10 · House clinical team